

+UNIVERSITY OF MIAMI  
Curriculum Vitae  
Standard Format

1. Date: October 1, 2014

I PERSONAL:

2. Name: Mark S. Goodman

3. Office: (305) 243-6520

Address: 1475 NW 12th Avenue Suite: 3400  
Miami, FL 33136

4. Fax: (305) 243-5239

5. E-mail:

6. Current Academic

Rank: Associate Professor of Medicine

7. Primary Dept: Medicine, Hematology/Oncology

8. Citizenship: USA

II HIGHER EDUCATION:

B.S. in Biology/Philosophy 1978 - 1982

Tulane University

University of Miami 1982 - 1986  
School of Medicine

University of Miami 1986 - 1987  
Internship

University of Miami 1987 - 1989  
Residency in Medicine

University of Miami 1991 - 1993  
Fellowship - Hematology/Oncology

CERTIFICATION:

Florida State License	1988
D.E.A.	1988
Internal Medicine Board Certification	1989
Hematology Board Certification	1994
Oncology Board Certification	1995

HONORS & AWARDS:

Cum Laude	1982
Alpha Omega Alpha	1987
Phi Kappa Phi	1987

MEMBERSHIPS:

ECOG	1995
ASCO	1995
ASBMT	1998
ASH	2005

III EXPERIENCE:

Assistant Professor of Medicine General Medicine University of Miami	1989 - 1991
Director, Nutritional Support Team Veteran's Administration	1990 - 1991
Fellowship - Hematology/Oncology University of Miami	1991 - 1994
Assistant Professor of Medicine Hematology Oncology	1994 - 2007
Associate Professor of Medicine Hematology Oncology	2007- Present

Director of Bone marrow Transplant Program 6/2006- 7/2008

Bone Marrow Transplant Team  
Autologous & Allogeneic 1994 – Present  
University of Miami

Director of Hematology Elective UM 1994- present

#### IV PUBLICATIONS (ARTICLES):

Hardy L, **Goodman, M**, Vasquez A, Chauhan D, Anderson K, Voellmy R, Spector N. Activation Signals Regulate Heat Shock Transcription Factor 1 in Human B-Lymphocytes. *Journal of Cellular Physiology* 1997; 170:235-240.

Koya R, Andersen J, Fernandez H, **Goodman M**, Spector N, Smith R, Hanlon J, Cassileth PA. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. *Bone Marrow Transplantation* 1998; 21: 923-926.

**Goodman M**, Spector N, Rodrigues G, Cassileth PA. Interleukin-2 Therapy for Advanced Chronic Myeloid Leukemia. *Leukemia* 1998; 12 1682-1684.

**Goodman M**, Cabral L, Cassileth PA. Interleukin-2 and Leukemia. *Leukemia* 1998; 12 1671-1675.

**Goodman M** Pentostatin (Nipent) and High-dose Cyclophosphamide for the Treatment of Refractory Autoimmune Disorders. *Seminars in Oncology* 2000 27 suppl 5 67-71

Fernandez HF, Tran, HT, Albrecht, F; Caldera, H; **Goodman M**, MS Evaluation of Safety , Efficacy and Pharmacokinetics of Administering Twice Daily IV Busulfan (Busulfex) in patients with Advanced Hematologic Malignancies Undergoing Stem Cell Transplant (SCT). *Biology of Blood and Marrow Transplantation* 2001 p71

Bahlis NJ, McCafferty-Grad J, Jordon-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, **Goodman M**, Fernandez HF, Boise LH, Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. *Clinical Cancer Research* 2002 p3658

Xia W, Hardy L, Liu L, Zhao S, **Goodman M**, Voellmy R, Spector NL Concurrent exposure to heat shock and H7 synergizes to trigger breast cancer cell apoptosis while sparing normal cells. *Breast Cancer Research Treatment* 2003 p233

Dabaja MA, Morgensztern D, Santos E, **Goodman M**, Fernandez HF Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant. Bone Marrow Transplant 2003 31 129-131

Sergio Giralt, William Bensinger, **Mark Goodman**, Donald Podloff, Janet Eary, Richard Wendt, Raymond Alexanian, Donna Weber, David Maloney, Leona Holmberg, Joseph Rajandran, Hazel Breitz, Richard Ghallie, and Richard Champlin 166 Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1 / 2 trials Blood, Oct 2003:102 2684

Santos ES, , **Goodman M**, Byrnes JJ, Fernandez HF. Thalidomide effects in the post-transplantation setting in patients with multiple myeloma. Hematology 2004 9(1) : 35

Santos ES, Rosenblatt JD, **Goodman M**. Role of Farnesyltransferase inhibitors in hematologic malignancies . Expert Rev. Anticancer Ther. 2004 4(5) 843-856

Morgensztern D, Rosado M, Silva O, Santos E, Abdullah S, **Goodman M**, Hamilton-Nelson K, Rosenblatt J, Lossos I. Prevalence of Hepatitis C Infection in Patients with Non-Hodgkin's Lymphoma in South Florida and Review of the Literature. Leukemia and Lymphoma Dec 2004 45(12) 2459-2464

**Goodman M**. First, Do No Harm, Second, Make Sure You Are Doing Some Good Journal of Clinical Oncology 2005 23( 5) 1045-1046

**Goodman M**. Alemtuzumab until MDR for CLL: Is it now a new standard. Journal of Clinical Oncology 2005 23(28) 7240-7241

#### PUBLICATIONS (ABSTRACTS):

Fernandez, H.F., Noto, T.A., Morrell, N., **Goodman, M.**, Smith, R.T., Collier, T. and Cassileth, P.A. Early engraftment of mobilized autologous peripheral blood progenitor cells collected by large volume leukapheresis. Proceedings of ASCO, abst. #365, p. 94a, 1994.

Fernandez, H.F., Spector, N., **Goodman, M.**, Noto, T.A., Reik, R., Cassileth, P.A. Use of G-CSF mobilized allogeneic peripheral blood progenitor cells (pbpc) collected by large volume leukapheresis (LVI). Blood 86 (10):58 1a (abst. #2313), 1996.

**Goodman, M.**, Spector, N., Fernandez, H.F., Cassileth, P.A., Hurley, J., University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL. High Dose continuous infusion VP-16, Ifosfamide, SoluMedrol and Interleukin-2 (visit) in relapsed lymphoma and refractory hematologic malignancies. Blood 86 (10):813a (abst. #3240), 1996.

Restrepo A, Fernandez H.F., Morrell L, Spector N, **Goodman M**, Smith R.J., Hanlon J, Cassileth PA. Safety of High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Breast Cancer. Proceedings of ASCO, 1996 Vol. 15, p. 349.

Koya R, Fernandez H, **Goodman M**, Spector N, Smith R, Hanlon J, Cassileth P. Cost-effectiveness of blood cultures in autologous peripheral blood stem cell (PBSC) transplant patients. Proceedings of ASCO, 1997, p.418a.

**Goodman, M.**, Hardy, L., Voellmy, R., Spector, N. Selective sensitivity of leukemics to the cytotoxic effects of heat shock stimuli: mechanism and clinical application. Blood 88 (10):2559 (abst. 1008), 1997.

Rodrigues, G., **Goodman, M.**, Restrepo, A., Spector, N., Efficacy of Low Dose IL-2 in CML Blast Crisis and Accelerated Phase. Blood 88 (10):576a (abst. 2293) 1997.

Morrell L, Fernandez H.F., Krill e, **Goodman M**, Spector N, Hanlon J, Cassileth P.A.. High Dose Chemotherapy (HDC) and Peripheral Blood Stem Cell (PBSC) Transplantation in Inflammatory Breast Cancer. Proceedings of ASCO, 1996, p. 332.

Henao-Uribe AM, Fernandez HF, Viciano AL, **Goodman M**, Bartlett-Pandite L, Cassileth PA., Mobilization of Peripheral Blood Stem Cell (PBSC) without Chemotherapy, using Filgrastim (G-CSF) and Large Volume Leukapheresis (LVL). Blood 92 (10) (abst. 4293) 1998.

Caldera H, Ruez L, Hildron A, Henao A, **Goodman M**. Leukemic Meningitis in B-Cell Chronic Lymphocytic Leukemia (CLL). Blood 92 (10) (abst. 4123) 1998.

Hugo Fernandez, Mark Goodman , Lini Pandite Busulfan and Cyclophosphamide Conditioning Regimen for Autologous Stem Cell Transplant in Patients with NonHodgkins Lymphoma Blood 94 (10) abst # 4818 1999,Oral

W. Besinger, S. Giralt, J. Eary, K. Thielke, JK Bryan, P. William, L. Holmberg, R. Alexanian, **M Goodman**, A. Serafini, D. Podoloff, R. Champlin, Phase I-II Study of holmium –DOTMP in Combination with Melphalan-Total Body Irradiation (TBI) with Autologous Peripheral Blood Stem Cell Transplant (PBSCT) for patients with Multiple Myeloma (MM) Proceedings of ASCO 2000 abst#26

HF Fernandez, H. Caldera, **MS Goodman**, RJ Smith, JD Hanlon, PA Cassileth. The Treatment of Poor Prognosis Breast Cancer with High Dose Cyclophosphamide, Thiotepa and Peripheral Blood Stem Cell (PBSC) Rescue.Proceedings of ASCO 2000 abst 515

Sergio Giralt, Richard Champlin, **Mark Goodman**, et al Preliminary Results of A Phase I/II Study of multiple Myeloma (MM) Patients Treated with 166 Holmium-Dotmpin Combination with high Dose Melphalan+/- Total Body Irradiation (TBI) with Autologous Stem Cell Transplant . Blood 2000 558a

## V. Professional

### Selected research

Phase I-II trial of VP-16, Ifosfamide, Solumedrol and Interleukin-2 for relapsed lymphoma (visit).

Phase III study of priming with Granulocyte-Macrophage colony stimulating factor (rhu-GM-CSF) and of three induction regimens in adult patients (over 55) with acute non-lymphocytic leukemia. ECOG #3993.

Phase II trial of intermediate dose ARA-C cyto reduction and IL-2 and Alfa-Interferon maintenance in the treatment of chronic myelogenous leukemia in blast crisis and accelerated phase.

Phase II Multicenter Study of AR-623 (Liposomal-Tretinoin) in patients with APL following first or subsequent relapse.

Phase II trial of Intermediate dose Ara-C cyto reduction and IL-2 and alpha- Interferon maintenance in the Treatment of Chronic Myelogenous Leukemia In Blastic Crisis and Accelerated Phase

Randomized Controlled Study to Determine Incremental Activity and Safety of 131 Iodine-Radiolabeling of Anti-B1 Antibody in Chemotherapy Refractory Low Grade Non-Hodgkin's Lymphoma in Comparison to Unlabeled Anti B1- Coulter Pharmaceutical

Phase II/III Study of 131 Lym-1 in the Treatment of intermediate or High Grade Refractory Non-Hodgkin's Lymphoma-Techniclone Pharmaceutical

A phase II Open-Label Study to Determine the Safety and Anti-Leukemic Effects of STI571 with Philadelphia Chromosome- Positive Chronic Myeloid leukemia in Myeloid Blast Crisis

Immunosuppression for Non-Hematologic Autoimmune Disease (SCCC1998044)

Phase II Study Genasense (BCl-2 Anti sense) Combined with Molotarg (gemtuzumab ozogamicin) in Elderly Patients with relapsed Acute Myeloid Leukemia

An Open Label , Prospective , Stratified, Randomized , Controlled , Multi-Center , Phase IIB Study of the Impact of Thymoglobulin Therapy on Transfusion Needs of Patients with Early Myelodysplastic Syndrome

A Phase II Open Label Randomized, Dose and Schedule Finding, Clinical Trial of Immunotherapy with AMG 412 in Subjects with Diffuse Large B-Cell Non Hodgkin's Lymphoma

Phase I Clinical trial of Dose Escalated Bortezomib and Arsenic Trioxide + Melphalan As A Conditioning Regimen For Multiple Myeloma

A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF MAINTENANCE THERAPY WITH CC-5013 (NSC # 703813, IND # 70116) OR PLACEBO FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA; SCCC 2006024

SCCC 2008030: A PHASE 2 OPEN-LABEL, MULTICENTER CLINICAL STUDY OF THE SAFETY AND EFFICACY OF VORELOXIN INJECTION IN PATIENTS > 60 YEARS OF AGE WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA

A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure; SCCC 2004140

A PHASE I/II STUDY OF GEMTUZUMAB OZOGAMICIN (MYLOTAG) GIVEN IN CONJUNCTION WITH BUSULFAN AND CYTOXAN IN RELAPSED OR HIGH RISK PATIENTS WITH ACUTE MYELOID LEUKEMIA SCCC 2001003

A PHASE I/II STUDY OF GEMTUZUMAB OZOGAMICIN (MYLOTAG) GIVEN IN CONJUNCTION WITH BUSULFAN AND CYTOXAN IN RELAPSED OR HIGH RISK PATIENTS WITH ACUTE MYELOID LEUKEMIA SCCC 2001003

VI Teaching

Awards:

William Harrington Award for Teaching 2004

Teaching responsibilities:

1. Lecture to incoming hematology/oncology fellows on Hematologic malignancy and coagulopathies on Thursday mornings
2. Attend weekly Hematology Clinic at JMH –Supervise and instruct fellows and medical students in the care of hematologic disorders. Patient’s treatment plans are developed.
3. Attend on hematology inpatient service ( WW12 JMH) round daily on inpatient hematologic patients. Usually 3-4 months a year
4. Orchestrate weekly bone marrow transplant meeting attended by physicians , nurses, social workers and pharmacy
5. Leukemia rounds weekly on in patient services : Fellows, Residents, Medical students

#### PRESENTATIONS AND INVITED LECTURES:

Update of Cytokine Therapy in Hematology-32 Annual Postgraduate Course “Internal Medicine Update 1997”

Hemostasis and Thrombosis –Medical Student 4<sup>th</sup> year lecture series 1997

Chronic Myelogenous Leukemia –Immunologic Aspects Dept of Immunology Grand Rounds 1998

Advances in the Treatment of Chronic Myelogenous Leukemia –Bone Marrow Transplant Update 1998

Bone Marrow Transplant in the Treatment of Lymphoma 1998-Grand Rounds Naples Community Hospital 1998

Hypercoagulable States-33 Annual Postgraduate Course ”Internal Medicine Update 1998”

Thrombophilia and New Approaches to the Treatment of Venous Thrombosis-Mercy Hospital Grand Rounds 1998

New Approaches In the Treatment of Low Grade Lymphoma 1999- Lymphoma and Leukemia Society of America

Antiphospholipid Syndrome and Heparin Induced Thrombocytopenia 1999 Mercy Hospital Medical Grand Rounds

Transplantation of Autoimmune Diseases –1999 Focus on Blood and Marrow Transplantation

Pri\_med conference “ “Current Clinical Issues in Primary Care “ –Managing Thrombotic Disorders 2000

Update of Internal Medicine “Hypercoagulable States” University of Miami 4/2000

Treatment of Low Grade lymphomas Nuclear Medicine Grand rounds Jackson Memorial Hospital 5/2000



Can we Improve on the Therapy of Newly Diagnosed Large Cell Lymphoma 3/2001-  
Jupiter Oncology Conference  
Why Nothing Works 2005  
Thrombocytopenia : Board review 2006  
Coagulopathies Board review 2006

## VII Service

Intern Selection Committee	1999-2002
Director of UMHC inpatient unit	2004- 2006
Fellows advisory committee	2002- 2008
Transfusion committee	2005- present

